Results 121 to 130 of about 9,290 (250)

CRISPR‐Scan: Cas13a Mismatch Tolerance Enabled Ultra‐Multiplexed Detection of Same‐Site Indels in Acute Myeloid Leukemia

open access: yesAdvanced Science, EarlyView.
Accurately detecting diverse same‐locus insertions or deletions (indels) remains challenging. This study reveals the mismatch‐tolerance profile of LwaCas13a and establishes CRISPR‐Scan, which uses a single crRNA to detect multiple same‐locus indels. The one‐pot assay detects nucleophosmin 1 (NPM1) mutant allele frequencies down to 0.01%, agrees with ...
Linlin Bai   +13 more
wiley   +1 more source

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

open access: yesAdvanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi   +13 more
wiley   +1 more source

Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21

open access: yesAdvanced Science, EarlyView.
EGFR mutations drive a substantial fraction of non‐small cell lung cancers (NSCLC) and are effectively targeted by tyrosine kinase inhibitors (TKIs), including osimertinib. However, resistance inevitably develops through secondary mutations and compensatory receptor activation, including the GAS6 receptor MERTK.
Suvendu Giri   +28 more
wiley   +1 more source

Spatiotemporally Precise Rheumatoid Arthritis Therapy via a Triple‐Locked Cascaded Nanoplatform With Dual‐Channel Self‐Reporting

open access: yesAdvanced Science, EarlyView.
An orthogonally programmable nanotheranostic (MB@YW NPs) enables precision therapy for rheumatoid arthritis. A triple‐locked (pH, HOCl/ONOO−, light) independently drives the release of methotrexate and sulfasalazine. Trackable by dual‐channel fluorescence, this coordinated drug delivery remodels the inflammatory microenvironment to markedly suppress ...
Jihong Liu   +11 more
wiley   +1 more source

In Vivo CRISPR Screen Identifies RPS19 as an Immunotherapy Target in Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
By employing in vivo CRISPR functional screening, we identify ribosomal protein RPS19 as a pivotal mediator driving immune evasion in hepatocellular carcinoma, wherein tumor‑released RPS19 binds C5aR1 on tumor‑associated macrophages to initiate downstream immunosuppressive signaling; SP94‑peptide‑modified SNPSS nanoparticles deliver Cas9/sgRPS19 ...
Lei He   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy